Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease

FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease

US Patent 11752173 · Granted Sep 12, 2023

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Method of treating diabetes with FGF21 and GLP1 double gene-modified cell2025
Method of treating diabetes with FGF21 and GLP1 double gene-modified cell2025
Method of treating diabetes with FGF21 and GLP1 double gene-modified cell2025
Method of treating diabetes with FGF21 and GLP1 double gene-modified cell2025
System and method for battery selection2025
Battery module lithium plating reduction2025
State of charge dependent plating estimation and prevention2025
Method for quickly optimizing key mining parameters of outburst coal seam2024
Methods for obtaining and correcting biological sequence information2024
Cooling strategy for battery systems2024
Methods for obtaining and correcting biological sequence information2023
State of charge dependent plating estimation and prevention2023